Kurma Partners announced the first closing of its Growth Opportunities fund at €160m. Meeting the demand of the growing maturity of the European biotech and healthtech ecosystem, this new fund, which is targeting €250m, aims to accelerate the growth of the best European companies in the healthcare sector.
For this fund, Kurma Partners has received the support of the European Investment Fund (EIF), Bpifrance1, the Belgian Growth Fund managed by PMV and BNP Paribas Fortis Private Equity, SFPI, BNP Paribas Fortis and Groupe Pasteur Mutualité. Eurazeo, which recently increased its stake in Kurma Partners, is also an anchor investor in this fund.
With this new fund, Kurma Partners now covers the entire financing spectrum, from company creation to the most advanced phases of development, in the biotech and healthtech sectors in which its teams have recognized expertise. The fund will mainly target unlisted European companies, addressing strong medical needs, in transformation from R&D-stage to being a commercial-stage company. In launching this Growth Fund, Kurma Partners is leveraging the convergence of scientific and sectoral expertise, entrepreneurial know-how and financial capacity. The objective is to invest in around 15 companies.
Read more: Business Wire
